Explore
Validate
LearnBMS113
antibody from Invitrogen Antibodies
Targeting: CD44
CD44R, CSPG8, HCELL, IN, MC56, MDU2, MDU3, MIC4, Pgp1
Immunohistochemistry
Other assayAntibody data
- Antibody Data
- Antigen structure
- References [1]
- Comments [0]
- Validations
- Other assay [1]
Submit
Validation data
Reference
Comment
Report error
- Product number
- BMS113 - Provider product page
- Provider
- Invitrogen Antibodies
- Product name
- CD44std Monoclonal Antibody (SFF-2), eBioscience™
- Antibody type
- Monoclonal
- Antigen
- Other
- Description
- Description: BMS113 specifically recognizes human standard CD44, but cannot be used to distinguish between splice variants (exon v3-v10). CD44 is a cell membrane associated, polymorphic glycoprotein with apparent molecular weights ranging from 85 kDa to 250 kDa. CD44 isoforms participate in a wide variety of cell-cell or cell-matrix interactions including lymphocyte homing, establishment of B and T cell immune responses, tumor metastases formation and inflammation. Three isoform categories of the CD44 molecule have been identified: 1) an 80-90 kDa isoform, the so-called standard form named CD44std, which is widely distributed on several hematopoietic and nonhemato-poietic cells including all subsets of leukocytes, monocytes, erythrocytes, many types of epithelium, mesenchymal elements like fibroblasts, smooth muscle cells and glial cells of the central nervous system, 2) a medium size category of 110-160 kDa which is weakly expressed on epithelial cells and highly expressed in some carcinomas and 3) a category which includes very large isoforms of 250 kDa covalently modified by the addition of chondroitin sulfate. These bigger isoforms of CD44 arise by alternative splicing of one or more ""variant"" exons (v2-v10) into the extracellular part of the 90kDa constant form molecule. Compared to the standard CD44, all larger isoforms are expressed in a much more restricted fashion, only in a few normal tissues or on the surface of certain tumor cells. Some splice variants of CD44 play important and distinct roles in tumor metastasis. Applications Tested: Flow Cytometry, Immunohistochemistry (Paraffin). Purity: >95%.
- Reactivity
- Human
- Host
- Mouse
- Isotype
- IgG
- Antibody clone number
- SFF-2
- Vial size
- 100 µg
- Concentration
- 1 mg/mL
- Storage
- -20°C
Submitted references Hyaluronidase reduces human breast cancer xenografts in SCID mice.
Shuster S, Frost GI, Csoka AB, Formby B, Stern R
International journal of cancer 2002 Nov 10;102(2):192-7
International journal of cancer 2002 Nov 10;102(2):192-7
No comments: Submit comment
Supportive validation
- Submitted by
- Invitrogen Antibodies (provider)
- Main image
- Experimental details
- 3 Staining of xenograft breast tumor sections. Tumors were obtained from SCID mice bearing human tumors derived from the breast carcinoma cell line MDA435. Sections were stained for HA, CD44s and CD44 variant v7-8. Tumors were harvested on Day 12 after the start of hyaluronidase treatment. Treatment consisted of 4 i.v. injections of 75 rTRU of hyaluronidase on Days 0, 2, 4 and 6. Histolocalization of HA using the biotinylated hyaluronan-binding peptide in ( a ) untreated mice with mock inoculation and ( b ) after hyaluronidase treatments. Immunolocalization of CD44s using monoclonal antibodies in ( c ) untreated mice and ( d ) after hyaluronidase treatment. Immunolocalization of CD44 variant v7-8 in ( e ) untreated mice and ( f ) after hyaluronidase treatment. Magnification = x200.
